Allosteric Chromenone Inhibitors for Selective PI3Kα Targeting
Solution Overview
Problem
Current PI3Kα inhibitors are nearly equipotent to wild-type and mutant PI3Kα, lacking selectivity, which limits their therapeutic window and increases toxicity, as they cannot effectively target mutant PI3Kα without affecting wild-type PI3Kα, leading to compensatory insulin and glucose production that negates their antiproliferative effects in cancer cells.
Innovation Solution
Development of a new class of allosteric chromenone inhibitors that selectively target a peripheral binding pocket near known mutations, such as H1047R, in the PI3Kα enzyme, allowing for enhanced selectivity towards mutant PI3Kα over wild-type, thereby inhibiting pathologic signaling in cancer cells without affecting systemic metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PI3Kα inhibitors are used, then PI3Kα activity is inhibited, but selectivity between mutant and wild-type PI3Kα is lost, leading to increased toxicity
Solution Approach 1:
The patent applies local quality by designing inhibitors that specifically target the unique structural features of the mutant PI3Kα binding pocket (created by mutations like H1047R, E545K, E542K) rather than the conserved ATP-binding site. The chromenone core structure with specific substituents (R1-R6, R9, Ring A) is configured to fit the distorted hydrophobic pocket formed by mutant residues, providing selective inhibition of mutant isoforms while sparing wild-type PI3Kα and other PI3K family members.
Solution Approach 2:
The patent inverts the conventional inhibition strategy by not targeting the active site (ATP-binding pocket) but rather an allosteric pocket that is created or enlarged by specific mutations. This inverted approach allows the inhibitor to bind to a region that is structurally altered in mutants, achieving reverse selectivity where mutant forms are preferentially inhibited over wild-type forms.
2Reliability
If selective inhibition of mutant PI3Kα is achieved, then therapeutic window is improved, but inhibitor design complexity increases
Solution Approach 1:
The patent segments the inhibitor molecule into distinct functional regions: a chromenone core structure (providing the allosteric binding interaction), substituent groups R1-R6 (fine-tuning selectivity and affinity), R9 (modulating pharmacokinetic properties), and Ring A (additional binding interactions). This segmentation allows systematic optimization of each region to achieve the desired balance between selectivity, affinity, and drug-like properties.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical parameters of the chromenone structure (different substituents at R1-R6 positions, different Ring A moieties, different R9 groups) to optimize the binding affinity and selectivity profile. This structure-activity relationship (SAR) approach allows tuning of the inhibitor's properties to achieve optimal therapeutic window while maintaining reasonable structural complexity.
3Productivity
If wild-type PI3Kα is inhibited, then cancer cell proliferation is suppressed, but compensatory insulin and glucose production negates the effect
Solution Approach 1:
The patent converts the harm of wild-type PI3Kα inhibition (which triggers compensatory metabolic responses) into a benefit by achieving such high selectivity for mutant forms that wild-type inhibition is minimized to below clinically significant levels. The selective inhibitors exploit the structural differences introduced by mutations to preferentially bind mutant PI3Kα, thereby suppressing tumor cell proliferation without triggering the harmful compensatory insulin and glucose production that occurs with non-selective inhibitors.
Data Source
AI summary
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I):or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.



